Kristina Bardova

Dr. Kristina Bardova

Institute of Physiology, AS CR
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2011 in International Journal of Obesity
Verified
Journal Article
Closed access
DMD Medrikova
D Medrikova
ZJZuzana Macek Jilkova
Zuzana Macek Jilkova
Kristina BardovaKristina Bardova
Kristina Bardova
PJP Janovska
P Janovska
MRM Rossmeisl
M Rossmeisl
JKJan Kopecky
Jan Kopecky

16 April 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
OHOlga Horakova
Olga Horakova
PKPetra Kroupova
Petra Kroupova
Kristina BardovaKristina Bardova
Kristina Bardova
JBJana Buresova
Jana Buresova
PJPetra Janovska
Petra Janovska
MRMartin Rossmeisl
Martin Rossmeisl
Metformin is currently the most prescribed drug for treatment of type 2 diabetes mellitus in humans. It has been well established that long-term treatment with metformin improves glucose tolerance in mice by inhibiting hepatic gluconeogenesis. Interestingly, a single dose of orally administered metformin acutely lowers blood glucose levels, however, little is known about the mechanism involved in this effect. Glucose tolerance, as assessed by the glucose tolerance test, was improved in response to prior oral metformin administration when compared to vehicle-treated mice, irrespective of whether the animals were fed either the standard or high-fat diet. Blood glucose-lowering effects of acutely administered metformin were also observed in mice lacking functional AMP-activated protein kinase, and were independent of glucagon-like-peptide-1 or N-methyl-D-aspartate receptors signaling. [18F]-FDG/PET revealed a slower intestinal transit of labeled glucose after metformin as compared to vehicle administration. Finally, metformin in a dose-dependent but indirect manner decreased glucose transport from the intestinal lumen into the blood, which was observed ex vivo as well as in vivo. Our results support the view that the inhibition of transepithelial glucose transport in the intestine is responsible for lowering blood glucose levels during an early response to oral administration of metformin.

1 February 2018 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
MBMarie Brezinova
Marie Brezinova
OKOndrej Kuda
Ondrej Kuda
JHJana Hansikova
Jana Hansikova
MRMartina Rombaldova
Martina Rombaldova
LBLaurence Balas
Laurence Balas
JKJan Kopecky
Jan Kopecky

6 December 2013 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
João TeodoroJoão Teodoro
João Teodoro
PZPetr Zouhar
Petr Zouhar
PFP Flachs
P Flachs
Kristina BardovaKristina Bardova
Kristina Bardova
PJP Janovska
P Janovska
JKJan Kopecky
Jan Kopecky

1 February 2014 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
MRMartin Rossmeisl
Martin Rossmeisl
DMDasa Medrikova
Dasa Medrikova
Evert Van SchothorstEvert Van Schothorst
Evert Van Schothorst
JPJana Pavlisova
Jana Pavlisova
OKOndrej Kuda
Ondrej Kuda
JKJan Kopecky
Jan Kopecky

31 August 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OHOlga Horakova
Olga Horakova
DMDasa Medrikova
Dasa Medrikova
Evert Van SchothorstEvert Van Schothorst
Evert Van Schothorst
ABAnnelies Bunschoten
Annelies Bunschoten
PFPavel Flachs
Pavel Flachs
JKJan Kopecky
Jan Kopecky
Insulin resistance, the key defect in type 2 diabetes (T2D), is associated with a low capacity to adapt fuel oxidation to fuel availability, i.e., metabolic inflexibility. This, in turn, contributes to a further damage of insulin signaling. Effectiveness of T2D treatment depends in large part on the improvement of insulin sensitivity and metabolic adaptability of the muscle, the main site of whole-body glucose utilization. We have shown previously in mice fed an obesogenic high-fat diet that a combined use of n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and thiazolidinediones (TZDs), anti-diabetic drugs, preserved metabolic health and synergistically improved muscle insulin sensitivity. We investigated here whether n-3 LC-PUFA could elicit additive beneficial effects on metabolic flexibility when combined with a TZD drug rosiglitazone. Adult male C57BL/6N mice were fed an obesogenic corn oil–based high-fat diet (cHF) for 8 weeks, or randomly assigned to various interventions: cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids (cHF+F), cHF with 10 mg rosiglitazone/kg diet (cHF+ROSI), cHF+F+ROSI, or chow-fed. Indirect calorimetry demonstrated superior preservation of metabolic flexibility to carbohydrates in response to the combined intervention. Metabolomic and gene expression analyses in the muscle suggested distinct and complementary effects of the interventions, with n-3 LC-PUFA supporting complete oxidation of fatty acids in mitochondria and the combination with n-3 LC-PUFA and rosiglitazone augmenting insulin sensitivity by the modulation of branched-chain amino acid metabolism. These beneficial metabolic effects were associated with the activation of the switch between glycolytic and oxidative muscle fibers, especially in the cHF+F+ROSI mice. Our results further support the idea that the combined use of n-3 LC-PUFA and TZDs could improve the efficacy of the therapy of obese and diabetic patients.